Protalix BioTherapeutics, Inc. (PLX) Key Metrics
PLX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $211.1M
- Enterprise value
- $194.2M
- P/E (TTM)
- 11.4
- Forward P/E
- 55.9
- PEG ratio
- —
- Price / sales
- 2.6 10-yr median 2.0
- Price / book
- 3.2 10-yr median 3.5
- EV / EBITDA
- 7.4 10-yr median 18.9
- Dividend yield
- —
- Beta
- −0.09
PLX key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsPLX valuation Price multiples at each fiscal year-end price.
PLX returns How much profit the business earns on the capital it uses.
PLX per-share figures Results divided by the shares outstanding at year-end.
PLX financial health Debt, liquidity and how easily interest is covered.
PLX efficiency & capital use Working capital cycle and where the cash goes.
PLX valuation history
PLX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
PLX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
PLX price vs earnings per share
PLX key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $141.4M | $152.4M | $146.7M | $66.4M | $36.7M | $105.8M | — | — | — | — |
| Enterprise value | $119.4M | $123.1M | $129.8M | $77.7M | $31.2M | $131.7M | — | — | — | — |
| P/E ratio | — | 52.0 | 17.7 | — | — | — | — | — | — | — |
| Price / sales | 2.7 | 2.9 | 2.2 | 1.4 | 1.0 | 1.7 | — | — | — | — |
| Price / book | 2.9 | 3.5 | 4.4 | — | — | — | — | — | — | — |
| Price / free cash flow | — | 20.6 | — | — | — | — | — | — | — | — |
| Price / operating cash flow | — | 17.6 | — | — | — | — | — | — | — | — |
| EV / sales | 2.3 | 2.3 | 2.0 | 1.6 | 0.8 | 2.1 | — | — | — | — |
| EV / EBITDA | — | 18.9 | 10.0 | — | — | 29.6 | — | — | — | — |
| EV / free cash flow | — | 16.7 | — | — | — | — | — | — | — | — |
| Earnings yield | −4.7% | 1.9% | 5.7% | −22.5% | −75.1% | −6.2% | — | — | — | — |
| Free cash flow yield | −9.6% | 4.9% | −1.7% | −38.6% | −32.0% | −25.3% | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Share price at fiscal year-end | $1.80 | $1.88 | $1.78 | $1.37 | $0.83 | $3.63 | $3.28 | $3.11 | $6.61 | $4.45 |
| Per share | ||||||||||
| Revenue per share | $0.67 | $0.66 | $0.79 | $0.98 | $0.87 | $2.16 | — | — | — | — |
| Earnings per share | −$0.08 | $0.04 | $0.10 | −$0.31 | −$0.62 | −$0.22 | — | — | — | — |
| Operating cash flow per share | −$0.15 | $0.11 | −$0.02 | −$0.52 | −$0.23 | −$0.90 | — | — | — | — |
| Free cash flow per share | −$0.17 | $0.09 | −$0.03 | −$0.53 | −$0.27 | −$0.92 | — | — | — | — |
| Cash per share | $0.39 | $0.43 | $0.54 | $0.46 | $0.88 | $1.32 | — | — | — | — |
| Book value per share | $0.61 | $0.53 | $0.41 | −$0.22 | −$0.14 | −$0.93 | — | — | — | — |
| Tangible book value per share | $0.61 | $0.53 | $0.41 | −$0.22 | −$0.14 | −$0.93 | — | — | — | — |
| Capex per share | $0.02 | $0.02 | $0.01 | $0.01 | $0.03 | $0.02 | — | — | — | — |
| Debt per share | $0.11 | $0.07 | $0.34 | $0.69 | $0.76 | $2.21 | — | — | — | — |
| Shares outstanding | 78.5M | 81.1M | 82.4M | 48.5M | 44.1M | 29.1M | — | — | — | — |
| Change in shares outstanding | −3.1% | −1.7% | +70.0% | +9.8% | +51.4% | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −14.4% | 7.6% | 72.5% | — | — | — | — | — | — | — |
| Return on invested capital (ROIC) | −21.6% | 18.1% | 117.0% | — | — | — | — | — | — | −481.9% |
| Return on assets (ROA) | −8.5% | 3.7% | 11.9% | −23.1% | −39.0% | −11.5% | −34.3% | −39.7% | −108.0% | −32.7% |
| Return on tangible assets | −8.0% | 4.0% | 9.8% | −26.8% | −37.4% | −9.6% | −40.3% | −43.3% | −115.5% | −35.7% |
| Free cash flow margin | −25.8% | 13.8% | −3.8% | −53.8% | −30.6% | −42.5% | −36.5% | −24.6% | −52.0% | −358.2% |
| Income quality (OCF / net income) | — | 2.96 | −0.16 | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $8.3M | $5.5M | $27.7M | $33.5M | $33.5M | $64.4M | $60.9M | $53.3M | $57.2M | $77.5M |
| Cash & short-term investments | $30.3M | $34.8M | $44.6M | $22.2M | $39.0M | $38.5M | $17.8M | $37.8M | $51.2M | $63.3M |
| Net debt | −$22.0M | −$29.3M | −$16.9M | $11.3M | −$5.5M | $25.9M | $43.1M | $15.4M | $6.1M | $14.2M |
| Debt / equity | 0.17 | 0.13 | 0.82 | — | — | — | — | — | — | — |
| Debt / assets | 0.10 | 0.08 | 0.33 | 0.60 | 0.45 | 0.95 | 1.34 | 0.87 | 0.79 | 0.94 |
| Net debt / EBITDA | — | −4.49 | −1.30 | — | — | 5.81 | — | — | — | — |
| Current ratio | 2.51 | 2.34 | 1.54 | 1.38 | 1.86 | 0.64 | 0.81 | 2.09 | 2.75 | 1.09 |
| Quick ratio | 1.54 | 1.52 | 1.12 | 0.87 | 1.32 | 0.49 | 0.61 | 1.75 | 2.41 | 1.01 |
| Interest coverage | -4.6 | 3.7 | 3.3 | -5.1 | -2.7 | 0.3 | -1.3 | -2.5 | -3.5 | -7.9 |
| Working capital | $40.2M | $34.5M | $24.4M | $12.5M | $28.5M | −$30.8M | −$7.7M | $27.6M | $39.9M | $5.7M |
| Invested capital | $26.3M | $13.9M | $16.7M | $654,000 | −$11.6M | −$1.2M | −$27.2M | −$37.4M | −$25.2M | $4.3M |
| Tangible asset value | $48.2M | $43.2M | $33.6M | −$10.6M | −$6.0M | −$27.0M | −$70.3M | −$52.9M | −$31.3M | −$10.0M |
| Net current asset value | $32.6M | $29.9M | $19.1M | −$21.5M | −$18.0M | −$39.2M | −$83.2M | −$61.0M | −$40.9M | −$20.3M |
| Graham number | — | $0.66 | $0.96 | — | — | — | — | — | — | — |
| Graham net-net per share | $0.20 | $0.21 | $0.09 | −$0.67 | −$0.66 | −$1.66 | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | $0 | $0 |
| Share buybacks (net) | $0 | $0 | $0 | $0 | $0 | $0 | — | — | $0 | $0 |
| Dividends + buybacks / free cash flow | — | 0.0% | — | — | — | — | — | — | — | — |
| Capex / revenue | 3.1% | 2.4% | 1.8% | 1.3% | 3.8% | 1.0% | 1.1% | 2.0% | 4.6% | 9.2% |
| Capex / operating cash flow | — | 14.8% | — | — | — | — | — | — | — | — |
| Capex / depreciation | 1.12 | 0.98 | 0.96 | 0.58 | 1.31 | 0.50 | 0.39 | 0.41 | 0.51 | 0.43 |
| Stock-based compensation / revenue | 4.4% | 6.1% | 5.3% | 4.4% | 6.2% | 5.0% | 1.5% | 1.5% | 1.6% | 10.7% |
| R&D / revenue | 36.1% | 24.3% | 26.1% | 61.6% | 77.5% | 60.7% | 81.6% | 97.3% | 136.8% | 330.6% |
| SG&A / revenue | 22.1% | 76.4% | 38.9% | 28.5% | 10.5% | 8.1% | 10.9% | 31.9% | 54.7% | 101.7% |
| Efficiency | ||||||||||
| Days sales outstanding | 40.7 | 28.0 | 27.5 | 30.8 | 25.9 | 19.4 | 31.5 | 34.4 | 20.9 | 54.9 |
| Days of inventory on hand | 311.6 | 302.3 | 284.7 | 323.8 | 346.4 | 356.5 | 280.1 | 321.8 | 156.7 | 239.3 |
| Days payables outstanding | 65.0 | 66.4 | 80.9 | 119.7 | 158.6 | 230.2 | 196.1 | 249.8 | 138.1 | 165.9 |
| Cash conversion cycle (days) | 287.3 | 263.9 | 231.3 | 234.8 | 213.8 | 145.7 | 115.5 | 106.4 | 39.5 | 128.2 |
| Receivables turnover | 8.98 | 13.05 | 13.29 | 11.87 | 14.09 | 18.78 | 11.60 | 10.62 | 17.46 | 6.65 |
| Payables turnover | 5.62 | 5.49 | 4.51 | 3.05 | 2.30 | 1.59 | 1.86 | 1.46 | 2.64 | 2.20 |
| Inventory turnover | 1.17 | 1.21 | 1.28 | 1.13 | 1.05 | 1.02 | 1.30 | 1.13 | 2.33 | 1.53 |
| Asset turnover | 0.68 | 0.68 | 0.93 | 0.74 | 0.54 | 1.11 | 1.03 | 0.51 | 0.27 | 0.10 |
| Average receivables | $5.9M | $4.1M | $4.9M | $4.0M | $2.7M | $3.4M | $4.7M | $3.2M | $1.2M | $1.4M |
| Average payables | $4.9M | $4.4M | $5.1M | $6.4M | $7.1M | $6.9M | $5.9M | $6.4M | $5.8M | $3.8M |
| Average inventory | $23.5M | $20.1M | $17.9M | $17.4M | $15.5M | $10.6M | $8.4M | $8.2M | $6.5M | $5.5M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from PLX's annual financial statements (latest annual report filed March 18, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
PLX valuation and financial ratios
Based on the latest twelve months, the trailing P/E is 11.4 and the forward P/E is 55.9. Protalix BioTherapeutics earned a return on equity of −14.4% and a return on invested capital of −21.6% in fiscal 2025. It ended the year with $8.3 million of debt and $30.3 million in cash and short-term investments, a net cash position of $22.0 million.
See the PLX income statement, the PLX chart for price history, or the PLX stock overview for the latest quote and news.
PLX key metrics FAQ
What is Protalix BioTherapeutics's P/E ratio?
Protalix BioTherapeutics's trailing P/E ratio is 11.4 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 55.9. At the end of fiscal 2025 it was —.
What is Protalix BioTherapeutics's return on equity?
Protalix BioTherapeutics's return on equity (ROE) was −14.4% in fiscal 2025: net income of -$6.6 million on average shareholders' equity of $45.7 million.
What is Protalix BioTherapeutics's ROIC?
Protalix BioTherapeutics's return on invested capital was −21.6% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Protalix BioTherapeutics have?
Protalix BioTherapeutics had total debt of $8.3 million at the end of fiscal 2025, a debt-to-equity ratio of 0.17 and more cash than debt.
What is Protalix BioTherapeutics's free cash flow yield?
Protalix BioTherapeutics generated -$13.6 million of free cash flow in fiscal 2025, a free cash flow yield of −9.6% on its market value at year-end ($141.4 million).
What is Protalix BioTherapeutics's current ratio?
Protalix BioTherapeutics's current ratio was 2.51 at the end of fiscal 2025: current assets were 2.51 times current liabilities.